Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients

Recruiting now

Conditions studied: Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect

In brief

The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.

Key facts

Study ID

NCT05326295

Run by

Hunan Cancer Hospital

People needed

1000

Starts

2019-03-01

Expected to finish

2029-03-01

Last updated by the study team

2022-04-13

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• The age is more than 18 years old;
• Pathology confirmed malignant breast tumor;
• No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection;
• Life expectancy is greater than 6 month;
• The main organ function is normal;
• The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance.

You may not qualify if…

• Patients who had suffered from other malignant tumors;
• With uncontrolled bacterial, viral or fungal infections;
• With physical or mental disorders
• Without or limited civil capacity;
• Infected with human immunodeficiency virus (HIV)；
• Circumstances in which the investigator considers it inappropriate to participate in this study.

Where it is running

• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.